Highly Potent Mini-Antibodies '1000 Times' Better at Neutralizing SARS-CoV-2 Could Be Promising Agents to Treat COVID-19
By HospiMedica International staff writers Posted on 06 Aug 2021 |
Illustration
Researchers have developed mini-antibodies that efficiently block the SARS-CoV-2 virus and its dangerous new variants.
These so-called nanobodies developed by scientists at the Max Planck Institute for Biophysical Chemistry (Göttingen, Germany) and the University Medical Center Göttingen (Göttingen, Germany) bind and neutralize the virus up to 1000 times better than previously developed mini-antibodies. In addition, the scientists optimized their mini-antibodies for stability and resistance to extreme heat. This unique combination makes them promising agents to treat COVID-19. Since nanobodies can be produced at low costs in large quantities, they could meet the global demand for COVID-19 therapeutics. The new nanobodies are currently in preparation for clinical trials.
The mini-antibodies (also known as VHH antibodies or nanobodies) unite all the properties required for a potent drug against COVID-19. At first glance, the new nanobodies hardly differ from anti-Sars-CoV-2 nanobodies developed by other labs. They are all directed against a crucial part of the coronavirus spikes, the receptor-binding domain that the virus deploys for invading host cells. The nanobodies block this binding domain and thereby prevent the virus from infecting cells. The scientists are currently preparing the nanobodies for therapeutic use.
“We want to test the nanobodies as soon as possible for safe use as a drug so that they can be of benefit to those seriously ill with COVID-19 and those who have not been vaccinated or cannot build up an effective immunity,” said Matthias Dobbelstein, professor and director of the University Medical Center Göttingen’s Institute of Molecular Oncology.
Related Links:
Max Planck Institute for Biophysical Chemistry
University Medical Center Göttingen
These so-called nanobodies developed by scientists at the Max Planck Institute for Biophysical Chemistry (Göttingen, Germany) and the University Medical Center Göttingen (Göttingen, Germany) bind and neutralize the virus up to 1000 times better than previously developed mini-antibodies. In addition, the scientists optimized their mini-antibodies for stability and resistance to extreme heat. This unique combination makes them promising agents to treat COVID-19. Since nanobodies can be produced at low costs in large quantities, they could meet the global demand for COVID-19 therapeutics. The new nanobodies are currently in preparation for clinical trials.
The mini-antibodies (also known as VHH antibodies or nanobodies) unite all the properties required for a potent drug against COVID-19. At first glance, the new nanobodies hardly differ from anti-Sars-CoV-2 nanobodies developed by other labs. They are all directed against a crucial part of the coronavirus spikes, the receptor-binding domain that the virus deploys for invading host cells. The nanobodies block this binding domain and thereby prevent the virus from infecting cells. The scientists are currently preparing the nanobodies for therapeutic use.
“We want to test the nanobodies as soon as possible for safe use as a drug so that they can be of benefit to those seriously ill with COVID-19 and those who have not been vaccinated or cannot build up an effective immunity,” said Matthias Dobbelstein, professor and director of the University Medical Center Göttingen’s Institute of Molecular Oncology.
Related Links:
Max Planck Institute for Biophysical Chemistry
University Medical Center Göttingen
Latest COVID-19 News
- Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles
- World's First Inhalable COVID-19 Vaccine Approved in China
- COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles
- Blood Viscosity Testing Can Predict Risk of Death in Hospitalized COVID-19 Patients
- ‘Covid Computer’ Uses AI to Detect COVID-19 from Chest CT Scans
- MRI Lung-Imaging Technique Shows Cause of Long-COVID Symptoms
- Chest CT Scans of COVID-19 Patients Could Help Distinguish Between SARS-CoV-2 Variants
- Specialized MRI Detects Lung Abnormalities in Non-Hospitalized Long COVID Patients
- AI Algorithm Identifies Hospitalized Patients at Highest Risk of Dying From COVID-19
- Sweat Sensor Detects Key Biomarkers That Provide Early Warning of COVID-19 and Flu
- Study Assesses Impact of COVID-19 on Ventilation/Perfusion Scintigraphy
- CT Imaging Study Finds Vaccination Reduces Risk of COVID-19 Associated Pulmonary Embolism
- Third Day in Hospital a ‘Tipping Point’ in Severity of COVID-19 Pneumonia
- Longer Interval Between COVID-19 Vaccines Generates Up to Nine Times as Many Antibodies
- AI Model for Monitoring COVID-19 Predicts Mortality Within First 30 Days of Admission
- AI Predicts COVID Prognosis at Near-Expert Level Based Off CT Scans